Here's a note from Alan W. Partin, MD, PhD, Chief Urologist and Director of the Department of Urology at Johns Hopkins. He's a famous research scientist known for the Partin Tables among other things. He thinks the STAMPEDE trial that showed the superiority of ADT (e.g., Lupron) + abiraterone (Zytiga) over ADT alone is the top story in prostate cancer for 2017.
practiceupdate.com/expertop...
Alan